Navigation Links
Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018
Date:11/9/2009

WALTHAM, Mass., Nov. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment. Continued uptake of Herceptin and Tykerb/Tyverb and the expected launches of three new therapies will drive sales of HER2-targeting agents to grow by 3.3 percent per year from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Breast Cancer finds that significant declines in sales in the hormonal therapy and chemotherapy segments of the market will be offset by a 1.2 percent annual increase in breast cancer incidence in the world's major markets and by the launch and uptake of premium-priced agents. Emerging HER2-targeting therapies that are expected to launch by 2018 include Roche/Chugai's Omnitarg, Roche's T-DM1 and Wyeth's HKI-272.

The report also finds that sales of Roche/Chugai's Avastin for breast cancer will increase by four percent from 2008 to 2018, largely owing to greater uptake by patients with metastatic disease.

"Since its approval, Avastin has garnered substantial patient share in metastatic breast cancer, particularly in the metastatic triple-negative and metastatic HR-refractory treatment settings, where there is a significant need for effective therapeutic options," said Decision Resources Analyst Niamh Murphy, Ph.D. "However, many of the physicians we interviewed, particularly in Europe, are not very enthusiastic about Avastin for breast cancer because they consider its cost-benefit profile suboptimal."

According to the report, experts are enthusiastic about the launch and uptake of a novel class of breast cancer therapies -- the poly ADP-ribose polymerase (PARP) inhibitors. The PARP inhibitors represent a novel therapeutic strategy in DNA-repair-deficient tumors, such as triple-negative breast cancer.

"PARP inhibitors, which include Sanofi-Aventis's BSI-201 and AstraZeneca's olaparib, could dramatically improve prognoses for the woefully underserved patient subgroups with DNA-repair-deficient tumors," Dr. Murphy said.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources            Decision Resources, Inc.
    Christopher Comfort           Elizabeth Marshall
    781-296-2597                  781-296-2563
    ccomfort@dresources.com       emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Recession Continues to Depress Sales at Allied Healthcare Products
2. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
3. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
4. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
5. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
6. HeartSine and Your Safety Company to Donate a Portion of Sales Proceeds to Sudden Cardiac Arrest Foundation
7. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
8. Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018
9. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
10. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
11. EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2017)... June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading ... announced new findings demonstrating positive biochemical outcomes related to ... One™. The data will be presented at the ERA-EDTA ... Madrid, Spain . The research ... Dialysis Network in Europe ...
(Date:5/30/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company ... will be presenting at the 7th annual LD Micro Invitational on ... , CEO, of DarioHealth will be giving the presentation and meeting ... 6th & 7th, 2017 at the Luxe Sunset Bel Air Hotel ... About LD Micro LD Micro ...
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... 27, 2017 , ... Two residents from the Gardant-managed assisted living and memory ... to encourage lawmakers to protect Medicaid funding. , The video, which was produced by ... story of Chuck and Cathy Schwarz, a couple who is still able to see ...
(Date:6/27/2017)... ... June 27, 2017 , ... Dr. Richard Amato, a respected ... his practice, Advanced Periodontics and Dental Implant Center of Connecticut. As part of the ... waiting areas. The renovations are intended to improve patient comfort while making it possible ...
(Date:6/27/2017)... ... ... Children’s National Health System received top honors in the 2017-18 U.S News & ... of more than 1500 neonatal intensive care units coast to coast. Children’s ... the top performing children’s hospitals in the country. , In addition to achieving ...
(Date:6/26/2017)... ... June 26, 2017 , ... Maryland’s soybean farmers have improved ... released by the United Soybean Board. , Thanks to the responsible use ... their productivity on less land per bushel, the report says. The United Soybean ...
(Date:6/26/2017)... ... ... New patients with missing teeth in Fitchburg, WI, can now ... Cotey is a trusted dentist who has placed many dental implants and enjoys teaching ... teeth in Fitchburg, WI, are encouraged to find out if they are candidates for ...
Breaking Medicine News(10 mins):